BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Bioequivalence Study for Acarbose / Metformin FDC

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Acarbose/Metformin FDC (BAY81-9783)
Drug: Acarbose (Glucobay, BAYG5421)
Drug: Metformin

First Posted Date: 2012-11-20

Last Posted Date: 2012-12-19

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT01728740

Open Label Study of BAY1082439 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BAY1082439

First Posted Date: 2012-11-19

Last Posted Date: 2018-01-30

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT01728311

First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Biological: BAY2010112

First Posted Date: 2012-11-08

Last Posted Date: 2019-09-27

Lead Sponsor: Bayer

Target Recruit Count: 47

Registration Number: NCT01723475

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)

Completed

Conditions: Multiple Sclerosis

Interventions: Biological: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2012-10-15

Last Posted Date: 2017-03-14

Lead Sponsor: Bayer

Target Recruit Count: 629

Registration Number: NCT01706055

Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

Phase 3

Completed

Conditions: Endometriosis

Interventions: Drug: EE20/DRSP(BAY86-5300)
Drug: Placebo
Drug: Dienogest

First Posted Date: 2012-10-02

Last Posted Date: 2016-02-18

Lead Sponsor: Bayer

Target Recruit Count: 312

Registration Number: NCT01697111

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

Not Applicable

Withdrawn

Conditions: Dermatitis, Atopic

Interventions: Drug: 1% Hydrocortison cream
Device: Phoenix (BAY81-2996)

First Posted Date: 2012-09-24

Last Posted Date: 2013-08-13

Lead Sponsor: Bayer

Registration Number: NCT01691209

Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution

Completed

Conditions: Infection

Interventions: Drug: Cipro (Ciprofloxacin, BAYQ3939)

First Posted Date: 2012-09-21

Last Posted Date: 2012-09-21

Lead Sponsor: Bayer

Target Recruit Count: 704

Registration Number: NCT01690559

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

Conditions: Gastrointestinal Stromal Tumors

First Posted Date: 2012-09-21

Last Posted Date: 2016-08-16

Lead Sponsor: Bayer

Registration Number: NCT01689376

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Completed

Conditions: Anti-Infective Agents

Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039)

First Posted Date: 2012-09-21

Last Posted Date: 2018-05-21

Lead Sponsor: Bayer

Target Recruit Count: 497

Registration Number: NCT01690533

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: BAY94-8862 (1.25mg)
Drug: BAY94-8862 (2.5mg)
Drug: BAY94-8862 (5mg)
Drug: BAY94-8862 (7.5mg)
Drug: BAY94-8862 (10mg)

First Posted Date: 2012-09-19

Last Posted Date: 2022-02-07

Lead Sponsor: Bayer

Target Recruit Count: 25

Registration Number: NCT01687920

Locations: 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy